Multi-Component Interactive Platform (MCIP)
The Multi-Component Interactive Platform (MCIP) is a proprietary technology developed by Evaeon that integrates modern pharmacokinetics (PK) and pharmacodynamics (PD) studies, bioactivity assays, and in silico modeling to identify and quantify the active pharmaceutical ingredient (API) in botanical drugs. The goal of this platform is to enable the establishment of a list of active substances from an herb or herbal formula with specified dosage and therapeutic effects.
Evaeon is currently implementing the MCIP to identify and screen active ingredients from natural Red Clover, Trifolium pratense, with the aim of developing a new botanical drug for the treatment of vaginal dryness. As women age, they undergo a natural menopausal transition period during which their bodies undergo numerous changes before reaching menopause. One significant change is a decline in the level of female hormones, particularly estrogen, which can lead to a range of undesirable physical and emotional changes known as menopausal symptoms.
Vaginal atrophy, characterized by vaginal dryness, is considered one of the most unpleasant menopausal symptoms, as it can cause discomfort during sexual activity and lead to vaginal infections, negatively affecting quality of life.
Hormone Replacement Therapy (HRT) is a common treatment for menopausal symptoms, which involves taking medicine containing estrogen to alleviate symptoms. However, HRT has been associated with an increased risk of vaginal bleeding, blood clots, heart attack, stroke, breast cancer, and other diseases.
Therefore, Evaeon is developing a new botanical drug using Red Clover, a dark-pink herbaceous plant, which contains four isoflavones that are considered natural phytoestrogens. These isoflavones mimic the effects of estrogen in the human body and can be used to improve symptoms related to female hormone deficiency caused by estrogen deficiency during menopause.
The MCIP approach involves three key steps: (1) extraction and identification of absorbable components from herbs or complex mixtures using proprietary technology, followed by analysis to estimate their distribution, metabolism, and potential interactions; (2) selection of molecular targets based on historical use of the herbs and pharmacological research using absorbable components and circulating metabolites; and (3) determination of pharmacokinetic and pharmacological properties of components, followed by a step-up process to identify the active ingredients and estimate optimal dosage for human use.
Through the use of MCIP, Evaeon has successfully identified, isolated, and determined the effective dosage of the active ingredients from natural Red Clover, Trifolium pratense, for the treatment of vaginal dryness.